Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.